These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 37862922)
1. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer. Chandnani N; Gupta I; Thakkar V; Sarkar K Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922 [TBL] [Abstract][Full Text] [Related]
2. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma. Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240 [TBL] [Abstract][Full Text] [Related]
3. Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC). Chandnani N; Choudhari VS; Talukdar R; Rakshit S; Shanmugam G; Guchait S; Gupta I; George M; Sarkar K Med Oncol; 2023 May; 40(7):185. PubMed ID: 37212947 [TBL] [Abstract][Full Text] [Related]
4. Polycomb recruitment at the Class II transactivator gene. Boyd NH; Morgan JE; Greer SF Mol Immunol; 2015 Oct; 67(2 Pt B):482-91. PubMed ID: 26283540 [TBL] [Abstract][Full Text] [Related]
5. PGC7 regulates H3K27me3 modification by inhibiting the interaction of YY1 with PRC2. Hao W; Huang C; Liu D; Xu H; Liu Y; Guan Y; Chen B; Guo Z Am J Physiol Cell Physiol; 2023 Jul; 325(1):C286-C299. PubMed ID: 37306391 [TBL] [Abstract][Full Text] [Related]
6. The roles of EZH2 in cancer and its inhibitors. Liu Y; Yang Q Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376 [TBL] [Abstract][Full Text] [Related]
7. Polycomb Repressive Complex 2 in Oncology. Guo Y; Yu Y; Wang GG Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005 [TBL] [Abstract][Full Text] [Related]
8. The noncanonical role of EZH2 in cancer. Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636 [TBL] [Abstract][Full Text] [Related]
9. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Caretti G; Di Padova M; Micales B; Lyons GE; Sartorelli V Genes Dev; 2004 Nov; 18(21):2627-38. PubMed ID: 15520282 [TBL] [Abstract][Full Text] [Related]
10. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. Au SL; Wong CC; Lee JM; Wong CM; Ng IO PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380 [TBL] [Abstract][Full Text] [Related]
11. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects. Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299 [No Abstract] [Full Text] [Related]
12. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer. Anwar T; Gonzalez ME; Kleer CG Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366 [TBL] [Abstract][Full Text] [Related]
13. Yin Yang-1 suppresses CD40 ligand-CD40 signaling-mediated anti-inflammatory cytokine interleukin-10 expression in pulmonary adventitial fibroblasts by promoting histone H3 tri-methylation at lysine 27 modification on interleukin-10 promoter. Pan YY; Yang JX; Xu YF; Mao W Cell Biol Int; 2020 Jul; 44(7):1544-1555. PubMed ID: 32198816 [TBL] [Abstract][Full Text] [Related]
14. Regulation of histone methylation by automethylation of PRC2. Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576 [TBL] [Abstract][Full Text] [Related]
15. YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators. Hoxha S; Shepard A; Troutman S; Diao H; Doherty JR; Janiszewska M; Witwicki RM; Pipkin ME; Ja WW; Kareta MS; Kissil JL Cancer Res; 2020 Jun; 80(12):2512-2522. PubMed ID: 32409309 [TBL] [Abstract][Full Text] [Related]
16. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009 [TBL] [Abstract][Full Text] [Related]
17. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis. Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Christofides A; Karantanos T; Bardhan K; Boussiotis VA Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053 [TBL] [Abstract][Full Text] [Related]
19. The role of EZH1 and EZH2 in development and cancer. Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells. Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]